D monetary help, paid to Wake Forest University School of Medicine, from Alnylam Pharmaceuticals, Gilead Sciences, and Mitsubishi Tanabe, NA; consulting fees from Alnylam Pharmaceuticals, Disc Medicine, Eiger Biopharmaceuticals, Protagonist Therapeutics, and Recordati Uncommon Ailments. Dr Gouya reported receiving travel support and monetary support from Alnylam Pharmaceuticals. Dr Aguilera-Peirreported getting advisory board costs from Alnylam Pharmaceuticals. Dr Bissell reported receiving financial support, paid to University of California, San Francisco, from Alnylam Pharmaceuticals. Dr Stein reported receiving consulting fees, registration reimbursement, and monetary support, paid to King’s College Hospital, from Alnylam Pharmaceuticals. Dr Balwani reported getting grant help, consulting charges, advisory board costs, and lecture charges from Alnylam Pharmaceuticals, advisory board fees fromRecordati Rare Illnesses, grant support and advisory board costs from Mitsubishi Tanabe, and advisory board fees from Alexion, Genzyme/Sanofi, and Takeda. In addition, Mount Sinai faculty are named Co-Inventors with Alnylam on a patent related to the development of givosiran, the study drug. The Icahn College of Medicine at Mount Sinai receives payments associated with this patent from Alnylam, plus a portion of these payments are also distributed to faculty and also other co-inventors. Dr Anderson reported receiving grant assistance and consulting charges from Alnylam Pharmaceuticals, Recordati Rare Ailments, and Mitsubishi Tanabe, and consulting charges from Moderna Therapeutics. Dr Parker reported getting monetary help, paid to University of Utah, from Alnylam Pharmaceuticals. Dr Kuter reported getting grant help and consulting charges from Actelion (Syntimmune), Agios, Alnylam Pharmaceuticals, Amgen, Argenx, Bristol Myers Squibb, Protalix, Rigel, and Takeda (Bioverativ), grant help from Kezar and Principia, and consulting charges from Caremark, Daiichi Sankyo, Dova, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Pfizer, Platelet Disorder Help Association, Principia, Protalix, Sanofi, Genzyme, Shionogi, Shire, UCB, Up-To-Date, and Zafgen. Dr Monroy reported receiving advisory board fees from Alnylam Pharmaceuticals. Dr Oh reported lecture charges from Merck, Pfizer, and Genzyme. Dr Ritchie reported getting consulting charges, paid towards the University of Alberta from Alnylam, Takeda, CSL Behring, and BioCryst, and grant help from CSL Behring and OctaPharma. Drs. Ko, Hua, and Sweetser reported becoming employed by and owning stock and stock solutions in Alnylam Pharmaceuticals. Dr Sardh reported receiving grant assistance and private fees, paid to Karolinska Institutet, from Alnylam Pharmaceuticals.PRDX5/Peroxiredoxin-5 Protein Biological Activity AU T H O R S C O N T R I B U T I O N S All authors had full access to all the information in the study and take responsibility for the integrity of your information and also the accuracy from the information analysis.IL-22 Protein web Idea and design and style: Anderson, Balwani, Bissell, Bonkovsky, Gouya, Sardh.PMID:24211511 Acquisition, evaluation, or interpretation of information: All authors. Drafting of the manuscript: Ko, Hua. Important revision of your manuscript for vital intellectual content: All authors. Statistical analysis: Hua. Supervision: Sardh, Ventura. Additional CONTRIBUTIONS Joseph Bloomer, MD (University of Alabama, USA), Daphne Vassiliou, MD, PhD (Karolinska University Hospital, Sweden), Elisabeth Minder, MD (Stadtspital Triemli, Switzerland), John Phillips, PhD (University of Utah College of Medicine, USA), David R.